Patents Assigned to VeroScience LLC
-
Patent number: 11883399Abstract: The present disclosure describes pharmaceutical formulations of bromocriptine and method of manufacturing and using such formulations. The formulations are useful for treating physiological disorders including improving glycemic control in the treatment of type 2 diabetes. Also disclosed is synthesis of bromocriptine citrate, and compositions and dosage forms containing bromocriptine citrate.Type: GrantFiled: May 3, 2022Date of Patent: January 30, 2024Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 11878974Abstract: Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.Type: GrantFiled: January 14, 2021Date of Patent: January 23, 2024Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 11666567Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.Type: GrantFiled: April 9, 2021Date of Patent: June 6, 2023Assignee: VeroScience LLCInventors: Anthony H. Cincotta, Craig Michael Bowe, Paul Clark Stearns, Laura Jean Weston
-
Patent number: 11607455Abstract: Methods for treating cancer and/or inducing tumor regression in mammals (e.g., humans) by increasing the metabolism of the mammal, administering a BA dye to the mammal, and thereafter exposing the tumor to actinic light for activation of the BA dye.Type: GrantFiled: September 23, 2020Date of Patent: March 21, 2023Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 11560375Abstract: Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.Type: GrantFiled: December 10, 2020Date of Patent: January 24, 2023Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 11510921Abstract: The present disclosure describes pharmaceutical formulations of bromocriptine and methods of manufacturing and using such formulations. The formulations are useful for treating physiological disorders including improving glycemic control in the treatment of type 2 diabetes. Also disclosed is synthesis of bromocriptine citrate, and compositions and dosage forms containing bromocriptine citrate.Type: GrantFiled: October 18, 2018Date of Patent: November 29, 2022Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 11241429Abstract: This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.Type: GrantFiled: April 29, 2020Date of Patent: February 8, 2022Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 11045464Abstract: This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.Type: GrantFiled: July 19, 2016Date of Patent: June 29, 2021Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 11000522Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.Type: GrantFiled: May 19, 2020Date of Patent: May 11, 2021Assignee: VeroScience LLCInventors: Anthony H. Cincotta, Craig Michael Bowe, Paul Clark Stearns, Laura Jean Weston
-
Publication number: 20210085787Abstract: Methods for treating cancer and/or inducing tumor regression in mammals (e.g., humans) by increasing the metabolism of the mammal, administering a BA dye to the mammal, and thereafter exposing the tumor to actinic light for activation of the BA dye.Type: ApplicationFiled: September 23, 2020Publication date: March 25, 2021Applicant: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 10894791Abstract: Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.Type: GrantFiled: October 27, 2017Date of Patent: January 19, 2021Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 10688094Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.Type: GrantFiled: April 24, 2019Date of Patent: June 23, 2020Assignee: VeroScience LLCInventors: Anthony H. Cincotta, Craig Michael Bowe, Paul Clark Stearns, Laura Jean Weston
-
Patent number: 10688155Abstract: The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.Type: GrantFiled: January 18, 2018Date of Patent: June 23, 2020Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 10675282Abstract: This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.Type: GrantFiled: February 7, 2019Date of Patent: June 9, 2020Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 10307421Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.Type: GrantFiled: May 16, 2018Date of Patent: June 4, 2019Assignee: VeroScience LLCInventors: Anthony H. Cincotta, Craig Michael Bowe, Paul Clark Stearns, Laura Jean Weston
-
Patent number: 10238653Abstract: This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.Type: GrantFiled: November 10, 2017Date of Patent: March 26, 2019Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 10137132Abstract: This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.Type: GrantFiled: May 7, 2014Date of Patent: November 27, 2018Assignee: VeroScience, LLCInventor: Anthony H. Cincotta
-
Patent number: 9999653Abstract: The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, Type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive CNS noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive CNS noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens.Type: GrantFiled: May 18, 2016Date of Patent: June 19, 2018Assignee: VeroScience LLCInventor: Anthony H. Cincotta
-
Patent number: 9993474Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.Type: GrantFiled: June 8, 2017Date of Patent: June 12, 2018Assignee: VeroScience LLCInventors: Anthony H. Cincotta, Craig Michael Bowe, Paul Clark Stearns, Laura Jean Weston
-
Publication number: 20180140675Abstract: The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.Type: ApplicationFiled: January 18, 2018Publication date: May 24, 2018Applicant: VeroScience LLCInventor: Anthony H. Cincotta